Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes.

Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR.

Diabetes Res Clin Pract. 2007 Aug;77(2):180-7. Epub 2007 Jan 18.

PMID:
17239474
2.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505
3.
4.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.

PMID:
11874944
5.
7.

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

Ann Intern Med. 2008 Oct 21;149(8):531-9.

PMID:
18936501
8.

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J; Rosiglitazone Clinical Trials Study Group.

Diabetes Care. 2001 Jul;24(7):1226-32.

PMID:
11423507
9.

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.

Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. Epub 2007 Dec 20.

PMID:
18095238
10.

Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus.

Reynolds LR, Konz EC, Frederich RC, Anderson JW.

Diabetes Obes Metab. 2002 Jul;4(4):270-5.

PMID:
12099976
12.

Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.

Rosenstock J, Chou HS, Matthaei S, Seidel DK, Hamann A.

Diabetes Obes Metab. 2008 Sep;10(10):862-73. doi: 10.1111/j.1463-1326.2007.00815.x. Epub 2008 Jan 14.

PMID:
18201206
13.

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.

Yilmaz H, Gursoy A, Sahin M, Guvener Demirag N.

Acta Diabetol. 2007 Dec;44(4):187-92. Epub 2007 Aug 29.

PMID:
17726570
15.

Diabetes treatments have differential effects on nontraditional cardiovascular risk factors.

Fonseca VA, Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry RR.

J Diabetes Complications. 2006 Jan-Feb;20(1):14-20.

PMID:
16389162
16.

Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.

Chou HS, Palmer JP, Jones AR, Waterhouse B, Ferreira-Cornwell C, Krebs J, Goldstein BJ.

Diabetes Obes Metab. 2008 Aug;10(8):626-37. Epub 2007 Jul 21.

PMID:
17645558
18.

Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.

Hollander P, Yu D, Chou HS.

Arch Intern Med. 2007 Jun 25;167(12):1284-90.

PMID:
17592102
20.

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP.

Curr Med Res Opin. 2006 Dec;22(12):2575-90.

PMID:
17166340

Supplemental Content

Support Center